Edition:
United Kingdom

Michael Erman

FDA downplays risks from already recalled heartburn drug Zantac

01 Nov 2019

NEW YORK The U.S. Food and Drug Administration on Friday downplayed the risk caused by contamination of the already recalled popular heartburn drug Zantac, and said its tests suggest it does not cause carcinogens to form after ingestion by patients.

UPDATE 2-FDA downplays risks from already recalled heartburn drug Zantac

01 Nov 2019

NEW YORK, Nov 1 The U.S. Food and Drug Administration on Friday downplayed the risk caused by contamination of the already recalled popular heartburn drug Zantac, and said its tests suggest it does not cause carcinogens to form after ingestion by patients.

Bristol-Myers posts better-than-expected results, Opdivo growth slows

31 Oct 2019

NEW YORK U.S. drugmaker Bristol-Myers Squibb Co reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.

FDA investigating whether Zantac causes carcinogens to form in users

24 Oct 2019

NEW YORK The U.S. Food and Drug Administration is investigating whether the popular heartburn drug Zantac causes carcinogens to form in the bodies of users, in an effort to fully understand the risks posed by the already recalled drug, the agency's spokesman said on Thursday.

Teva’s proposed opioid settlement could cost drugmaker pennies on the dollar

24 Oct 2019

NEW YORK/BOSTON Teva Pharmaceutical Industries Ltd's proposed $23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts.

Teva’s proposed opioid settlement could cost drugmaker pennies on the dollar

23 Oct 2019

NEW YORK/BOSTON Teva Pharmaceutical Industries Ltd's proposed $23 billion (£17.85 billion) drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts.

Sanofi pulls Zantac from U.S. and Canada after carcinogen found

19 Oct 2019

NEW YORK Sanofi SA said on Friday it would recall popular heartburn medicine Zantac in the United States and Canada, after the medicines were linked with a probable cancer-causing impurity.

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

28 Sep 2019

About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday.

Novartis blames former AveXis executives for Zolgensma data manipulation

24 Sep 2019

NEW YORK Novartis AG blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so.

World News